Clinical trials: Recurrent Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.
- Trial name
- NCT00093626
- Testing
- Laboratory Biomarker Analysis, Sorafenib Tosylate
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This is a study that will look at the effects and how useful investigational drug olaparib is as a neoadjuvant treatment (treatment given as to shrink a tumor before the main treatment) prior to surgery in patients with recurrent…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Neoadjuvant Treatment, Debulking Surgical Procedures
- Trial name
- NEO (NCT02489006)
- Testing
- Olaparib, Platinum-based Chemotherapy
- Where
- 9 sites in Canada, New Zealand and 2 more
- Volunteers
- 71 people
- Sponsor
- University Health Network, Toronto
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase II trial studies how well nivolumab works with or without ipilimumab in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer that has not responded after prior treatment…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02498600
- Testing
- Ipilimumab, Nivolumab
- Where
- 201 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapy, Tumor
Autologous OC-DC Vaccine in Ovarian Cancer
This is a Five cohort sequential clinical trial for subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer to determine the feasibility and safety as well as immunogenicity of OC-DC, an autologous vaccine…
- Conditions
- Chemotherapy, Tumor, Ovarian Cancer
- Trial name
- NCT01132014
- Testing
- OCDC
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-small Cell Lung Carcinoma (NSCLC), Melanoma
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
The purpose of this study is to evaluate the safety and tolerability of humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 (CM-24 [MK-6018]), administered intravenously as monotherapy and in combination with…
- Conditions
- Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02346955
- Testing
- CM-24 (MK-6018), Pembrolizumab (MK-3475)
- Where
- 3 sites in United States, Israel
- Volunteers
- 27 people
- Sponsor
- Famewave Ltd.
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well adavosertib with or without olaparib work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent).
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03579316
- Testing
- Adavosertib, Olaparib, Ceralasertib
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Carcinoma, Fallopian Tube Carcinoma
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT06420973
- Testing
- RC48+carboplatin±bevacizumab
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking University Cancer Hospital & Institute
Ovarian Cancer, Peritoneal Cavity Cancer
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227721
- Testing
- Docetaxel, Gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Robert Morris
Ovarian Cancer
Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004206
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- United Kingdom
- Sponsor
- University of Leicester
Recurrent Ovarian Cancer
Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent ovarian cancer.
- Trial name
- NCT02849353
- Testing
- Cryosurgery, NK immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Recurrent Ovarian Cancer, Fallopian Tube Cancer
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
The primary objective of this study is to investigate the feasibility, tolerability and safety of surgical debulking and resection with heated intraoperative chemotherapy (HIPEC) followed by repeated intraperitoneal chemotherapy…
- Trial name
- HIPEC (NCT01659554)
- Testing
- Cisplatin, Doxorubicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Ovarian Cancer, Advanced Epithelial Ovarian Cancer
A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian Cancer
The goal of this clinical trial was to evaluate the safety of Cellgram-DC, an autologous dendritic cell-based cancer immunotherapy, in patients with advanced or recurrent epithelial ovarian cancer.
- Conditions
- Ovarian Cancer, Advanced Epithelial Ovarian Cancer, Recurrent Epithelial Cancer of Ovary
- Trial name
- NCT04614051
- Testing
- Cellgram-DC
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Pharmicell Co., Ltd.
Solid Organ Tumors
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered and to understand how doctors may have used the results of the ChemoFx® to treat patients with…
- Trial name
- NCT01271959
- Where
- 25 sites in United States
- Volunteers
- 167 people
- Sponsor
- Precision Therapeutics
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
This phase II trial studies how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back (recurrent).
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT04034927
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well lapatinib works in treating patients with persistent or recurrent ovarian epithelial or…
- Trial name
- NCT00113373
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00072410
- Testing
- 90Y-hu3S193, 111In-hu3S193
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ludwig Institute for Cancer Research
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
This phase II trial is to see if combining bevacizumab with low-dose cyclophosphamide works in treating patients with ovarian epithelial or primary peritoneal cancer that has come back or spread to other parts of the body.
- Conditions
- Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer
- Trial name
- NCT00072566
- Testing
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Preference Study With Elderly Patients Recurrent Ovarian Cancer
Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)
- Trial name
- NCT00170690
- Testing
- Treosulfan
- Where
- Germany
- Volunteers
- 123 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial investigates how well pembrolizumab and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent).
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT04387227
- Testing
- Carboplatin, Pembrolizumab, Computed Tomography
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03907527
- Testing
- PRGN-3005 UltraCAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Precigen, Inc